Related Experiment Video
Updated: Nov 23, 2025

Author Spotlight: A Novel Method for Comprehensive Cell Component Analysis of Cerebral Blood Clots
Published on: July 21, 2023
The effect of race on composite thrombotic events in patients with COVID-19
Charles Esenwa1, Santiago R Unda2, David J Altschul3
1Department of Neurology, Montefiore Medical Center/Albert Einstein College of Medicine, United States of America.
Insights
Racial disparities in COVID-19 outcomes may not stem from biological differences. A study found no significant race-specific differences in thrombotic events among hospitalized COVID-19 patients, even after adjustments.
Area of Science:
- Medical research
- Epidemiology
- Cardiovascular medicine
Background:
- COVID-19 associated coagulopathy has been linked to mortality and racial disparities.
- Thrombotic complications are a significant concern in COVID-19 patients.
- Existing research suggests potential biological mediators for observed racial differences in COVID-19 severity.
Abstract:
COVID-19 associated coagulopathy and mortality related to thrombotic complications have been suggested as biological mediators in racial disparities related to COVID-19. We studied the adjusted prevalence of acute ischemic stroke, pulmonary embolism, myocardial infarction, and deep venous thrombosis stratified by race in hospitalized patients in one New York City borough during the local COVID-19 surge. The multi-racial cohort included 4299 patients hospitalized with COVID-19, 9% of whom were white, 40% black, 41% Hispanic and 10% Asian or other. We found a 6.1% prevalence of composite thrombotic events. There were no significant race-specific differences in thrombotic events when adjusting for basic demographics, socioeconomic factors, medical comorbidities or biomarkers using a stepwise regression model. We therefore found no evidence that the racial disparities related to COVID-19, and specifically thrombotic complications, are caused by biological differences in race.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Acute Coronary Syndrome III: Diagnostic Studies
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

